RAndomized Clinical Trial Of NAfamostat Mesylate, A Potent Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor, in patients with Covid-19 pneumonia: Safety SUPPLEMENTAL DATA

The file includes: Protocol of RACONA Study; Table S1: Seven-category ordinal scale; Table S2. Inclusion and ex-clusion criteria; Table S3. Flow-chart of the study; Table S4. Laboratory tests; Table S5. Secondary Outcomes; Table S6. Secondary biomarker endpoints; Table S7. Group-sequential design; Table S8. Completed trials of nafamostat mesylate for treatment of Covid-19 patients; Table S9. Ongoing trials of nafamostat mesylate for treatment of Covid-19 patients; Figure S1. Flow chart of the RACONA Study; Annex 1: CONSORT chart.